We found that EA combined with SFN restored skeletal muscle function in sarcopenia by activating the AMPK/Sirt1/PGC-1α pathway, inhibiting oxidative stress, apoptosis, and inflammation levels in skeletal muscle cells, and increasing the number and function of skeletal muscle mitochondria. The gene discussed is SIRT1; the disease is sarcopenia.